Regeneron’s Eylea fails combination study endpoint
pharmafile | October 3, 2016 | News story | Research and Development, Sales and Marketing | Eylea, Regeneron
Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness for treating wet age-related macular degeneration (AMD) when used in combination with rinucumab.
The 500-patient CAPELLA study found that the combination therapy was not as effective in treating AMD as Eylea alone; top-line results showed that both one and two doses of the combination therapy did not demonstrate an improvement in best corrected visual acuity (BCVA) at 12 weeks according to the Early Treatment Diabetic Retinopathy Scale. The combination treatment also did nothing to improve anatomic endpoints such as reduction in retinal thickness or resolution of sub-retinal hyper-reflective material.
The study will continue with data analysed again at 28 and 52 weeks.
Regeneron CSO George Yancopoulos remarked that “[we] look forward to the results of our ongoing combination studies of [Eylea] and nesvacumab, an anti-angiopoietin 2 antibody, for which the preclinical data is more supportive.”
AMD accounts for nearly half of all cases of blindness in the developed world and usually affects the elderly.
Regeneron’s shares fell 3.6% following the news.
Matt Fellows
Related Content
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its …
Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio
Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with …